Liposcale: A novel advanced lipoprotein test based on 2D diffusion-ordered 1H NMR spectroscopy

Journal of Lipid Research

Volumn 56, Issue 3, 2015, Pages 737-746

  Mallol, Roger ^a,b,c   Amigó, Núria ^a,b,c   Rodríguez, Miguel A ^b,d   Heras, Mercedes ^b,e   Vinaixa, Maria ^a,b   Plana, Núria ^b,e   Rock, Edmond ^f   Ribalta, Josep ^b,e   Yanes, Oscar ^a,b   Masana, Lluís ^b,c,e   Correig, Xavier ^a,b,c  

^a INSTITUT D INVESTIGACIÓ SANITÀRIA PERE VIRGILI IISPV   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c Biosfer Teslab   (Spain)

^d HOSPITAL UNIVERSITARI SANT JOAN DE REUS   (Spain)

^e UNIVERSITAT ROVIRA I VIRGILI   (Spain)

^f CEMAGREF   (France)

Author keywords

Cardiovascular risk; Low density lipoprotein particle number; Nuclear magnetic resonance; Two dimensional

Indexed keywords

APOLIPOPROTEIN A; APOLIPOPROTEIN B; APOB PROTEIN, HUMAN; APOLIPOPROTEIN B100; LOW DENSITY LIPOPROTEIN;

ADULT; AGED; ANALYTIC METHOD; ARTICLE; ATHEROGENIC DYSLIPIDEMIA; COHORT ANALYSIS; CONTROLLED STUDY; DIAGNOSTIC KIT; DIFFUSION COEFFICIENT; DYSLIPIDEMIA; FEMALE; HUMAN; ION MOBILITY; LIPOSCALE TEST; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PARTICLE SIZE; PRINCIPAL COMPONENT ANALYSIS; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTON NUCLEAR MAGNETIC RESONANCE; REPRODUCIBILITY; BLOOD; CLINICAL TRIAL; MIDDLE AGED; MULTICENTER STUDY; NUCLEAR MAGNETIC RESONANCE; PROCEDURES; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; APOLIPOPROTEIN B-100; APOLIPOPROTEINS A; DIABETES MELLITUS, TYPE 2; DYSLIPIDEMIAS; FEMALE; HUMANS; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE, BIOMOLECULAR;

EID: 84925310644     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.D050120     Document Type: Article

References (35)

1. Gerszten, R. E., and T. J. Wang. 2008. The search for new cardiovascular biomarkers. Nature. 451: 949-952.
2. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). 2002. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 106: 3143-3421.
3. Brunzell, J. D., M. Davidson, C. D. Furberg, R. B. Goldberg, B. V. Howard, J. H. Stein, and J. L. Witztum. 2008. Lipoprotein management in patients with cardiometabolic risk: consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation. J. Am. Coll. Cardiol. 51: 1512-1524.
4. Moin, D. S., and A. Rohatgi. 2011. Clinical applications of advanced lipoprotein testing in diabetes mellitus. Clin. Lipidol. 6: 371-387.
5. Mallol, R., M. A. Rodriguez, J. Brezmes, L. Masana, and X. Correig. 2013. Human serum/plasma lipoprotein analysis by NMR: application to the study of diabetic dyslipidemia. Prog. Nucl. Magn. Reson. Spectrosc. 70: 1-24.
6. Stein, J. H., and P. E. McBride. 2006. Should advanced lipoprotein testing be used in clinical practice? Nat. Clin. Pract. Cardiovasc. Med. 3: 640-641.
7. Jeyarajah, E. J., W. C. Cromwell, and J. D. Otvos. 2006. Lipoprotein particle analysis by nuclear magnetic resonance spectroscopy. Clin. Lab. Med. 26: 847-870.
8. Kaess, B., M. Fischer, A. Baessler, K. Stark, F. Huber, W. Kremer, H. R. Kalbitzer, H. Schunkert, G. Riegger, and C. Hengstenberg. 2008. The lipoprotein subfraction profile: heritability and identification of quantitative trait loci. J. Lipid Res. 49: 715-723.
9. Soininen, P., A. J. Kangas, P. Wurtz, T. Tukiainen, T. Tynkkynen, R. Laatikainen, M. R. Jarvelin, M. Kahonen, T. Lehtimaki, J. Viikari, et al. 2009. High-throughput serum NMR metabonomics for cost-effective holistic studies on systemic metabolism. Analyst. 134: 1781-1785.
10. Sniderman, A., and P. O. Kwiterovich. 2013. Update on the detection and treatment of atherogenic low-density lipoproteins. Curr. Opin. Endocrinol. Diabetes Obes. 20: 140-147.
11. Otvos, J. D., S. Mora, I. Shalaurova, P. Greenland, R. H. Mackey, and D. C. Goff, Jr. 2011. Clinical implications of discordance between low-density lipoprotein cholesterol and particle number. J. Clin. Lipidol. 5: 105-113.
12. Mackey, R. H., P. Greenland, D. C. Goff, Jr., D. Lloyd-Jones, C. T. Sibley, and S. Mora. 2012. High-density lipoprotein cholesterol and particle concentrations, carotid atherosclerosis, and coronary events: MESA (multi-ethnic study of atherosclerosis). J. Am. Coll. Cardiol. 60: 508-516.
13. Würtz, P., J. R. Raiko, C. G. Magnussen, P. Soininen, A. J. Kangas, T. Tynkkynen, R. Thomson, R. Laatikainen, M. J. Savolainen, J. Laurikka, et al. 2012. High-throughput quantification of circulating metabolites improves prediction of subclinical atherosclerosis. Eur. Heart J. 33: 2307-2316.
14. Cole, T. G., J. H. Contois, G. Csako, J. P. McConnell, A. T. Remaley, S. Devaraj, D. M. Hoefner, T. Mallory, A. A. Sethi, and G. R. Warnick. 2013. Association of apolipoprotein B and nuclear magnetic resonance spectroscopy-derived LDL particle number with outcomes in 25 clinical studies: assessment by the AACC Lipoprotein and Vascular Diseases Division Working Group on Best Practices. Clin. Chem. 59: 752-770.
15. Johnson, C. S. 1999. Diffusion ordered nuclear magnetic resonance spectroscopy: principles and applications. Prog. Nucl. Magn. Reson. Spectrosc. 34: 203-256.
16. Rock, E., B. M. Winklhofer-Roob, J. Ribalta, M. Scotter, M. P. Vasson, J. Brtko, R. Brigelius-Flohe, A. Bronner, and V. Azais-Braesco. 2001. Vitamin A, vitamin E and carotenoid status and metabolism during ageing: functional and nutritional consequences (VITAGE PROJECT). Nutr. Metab. Cardiovasc. Dis. 11: 70-73.
17. Schumaker, V. N., and D. L. Puppione. 1986. Sequential flotation ultracentrifugation. Methods Enzymol. 128: 155-170.
18. 1 H NMR spectroscopy data for the characterisation of human plasma lipoproteins. Metabolomics. 7: 572-582.
19. Petersen, M., M. Dyrby, S. Toubro, S. B. Engelsen, L. Norgaard, H. T. Pedersen, and J. Dyerberg. 2005. Quantification of lipoprotein subclasses by proton nuclear magnetic resonance-based partial least-squares regression models. Clin. Chem. 51: 1457-1461.
20. Bland, J. M., and D. G. Altman. 1999. Measuring agreement in method comparison studies. Stat. Methods Med. Res. 8: 135-160.
21. Cecconi, M., A. Rhodes, J. Poloniecki, G. Della Rocca, and R. M. Grounds. 2009. Bench-to-bedside review: the importance of the precision of the reference technique in method comparison studies-with specific reference to the measurement of cardiac output. Crit. Care. 13: 201.
22. Okazaki, M., S. Usui, A. Fukui, I. Kubota, and H. Tomoike. 2006. Component analysis of HPLC profiles of unique lipoprotein subclass cholesterols for detection of coronary artery disease. Clin. Chem. 52: 2049-2053.
23. Barter, P. J., C. M. Ballantyne, R. Carmena, M. C. Cabezas, M. J. Chapman, P. Couture, J. De Graaf, P. N. Durrington, O. Faergeman, J. Frohlich, et al. 2006. Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person/ten-country panel. J. Intern. Med. 259: 247-258.
24. Contois, J. H., J. P. McConnell, A. A. Sethi, G. Csako, S. Devaraj, D. M. Hoefner, and G. R. Warnick. 2009. Apolipoprotein B and cardiovascular disease risk: position statement from the AACC Lipoproteins and Vascular Diseases Division Working Group on Best Practices. Clin. Chem. 55: 407-419.
25. Lounila, J., M. Ala-Korpela, J. Jokisaari, M. J. Savolainen, and Y. A. Kesaniemi. 1994. Effects of orientational order and particle size on the NMR line positions of lipoproteins. Phys. Rev. Lett. 72: 4049-4052.
26. Dyrby, M., M. Petersen, A. K. Whittaker, L. Lambert, L. Norgaard, R. Bro, and S. B. Engelsen. 2005. Analysis of lipoproteins using 2D diffusion-edited NMR spectroscopy and multi-way chemometrics. Anal. Chim. Acta. 531: 209-216.
27. Ala-Korpela, M., N. Lankinen, A. Salminen, T. Suna, P. Soininen, R. Laatikainen, P. Ingman, M. Jauhiainen, M. R. Taskinen, K. Heberger, et al. 2007. The inherent accuracy of 1H NMR spectroscopy to quantify plasma lipoproteins is subclass dependent. Atherosclerosis. 190: 352-358.
28. Otvos, J. D., E. J. Jeyarajah, and W. C. Cromwell. 2002. Measurement issues related to lipoprotein heterogeneity. Am. J. Cardiol. 90: 22i-29i.
29. Ensign, W., N. Hill, and C. B. Heward. 2006. Disparate LDL phenotypic classification among 4 different methods assessing LDL particle characteristics. Clin. Chem. 52: 1722-1727.
30. Witte, D. R., M. R. Taskinen, H. Perttunen-Nio, A. van Tol, S. Livingstone, and H. M. Colhoun. 2004. Study of agreement between LDL size as measured by nuclear magnetic resonance and gradient gel electrophoresis. J. Lipid Res. 45: 1069-1076.
31. Caulfield, M. P., S. Li, G. Lee, P. J. Blanche, W. A. Salameh, W. H. Benner, R. E. Reitz, and R. M. Krauss. 2008. Direct determination of lipoprotein particle sizes and concentrations by ion mobility analysis. Clin. Chem. 54: 1307-1316.
32. Otvos, J. D., L. L. Rudel, and J. P. McConnell. 2008. Concerns regarding lipoprotein particle measurement by ion mobility analysis. Clin. Chem. 54: 2086-2087.
33. Caulfield, M. P., S. Li, G. Lee, P. A. Blanche, W. A. Salameh, W. H. Benner, R. E. Reitz, and R. M. Krauss. 2008. In reply. Clin. Chem. 54: 2088-2089.
34. Mazer, N. A., F. Giulianini, N. P. Paynter, P. Jordan, and S. Mora. 2013. A comparison of the theoretical relationship between HDL size and the ratio of HDL cholesterol to apolipoprotein A-I with experimental results from the Women's Health Study. Clin. Chem. 59: 949-958.
35. Hutchins, P. M., G. E. Ronsein, J. S. Monette, N. Pamir, J. Wimberger, Y. He, G. M. Anantharamaiah, D. S. Kim, J. E. Ranchalis, G. P. Jarvik, et al. 2014. Quantification of HDL particle concentration by calibrated ion mobility analysis. Clin. Chem. 60: 1393-1401.